Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Company-reported prevalence

Tovecimig

Overview

FieldValue
DrugTovecimig (CTX-009 and ABL001)
IndicationSecond-line advanced biliary tract cancer
DiseaseBiliary tract cancer (BTC)
CompanyCompass Therapeutics, Inc. (exclusive global rights outside South Korea, licensed from ABL Bio); ABL Bio, Inc. (originator and licensor); Handok Pharmaceuticals, Inc. (South Korea); Elpiscience Biopharmaceuticals Co., Limited (China, out-licensed by Compass Therapeutics)
Documents searchedCompass Therapeutics website: home and pipeline pages (accessed October 2026); Compass Therapeutics press releases dated April 25, 2024, January 2025, April 1, 2025, November 5, 2025, January 2026, March 2026, April 2026, May 2026, and August 2026; Compass Therapeutics Form 10-K for 2022 (March 2023), 2023 (March 2024), 2024 (February 2025), and 2025 (March 2026); Compass Therapeutics annual reports to shareholders (April 2025 and April 2026); Compass Therapeutics Form 10-Q for the second quarter of 2026 (August 2026); Compass Therapeutics corporate presentations (August 2025 and July 2026); Compass Therapeutics COMPANION-002 data presentation (April 2026); SEC full-text search of Compass Therapeutics filings for "diagnosed with BTC", "patients worldwide", and "eligible for tovecimig" (2023 to 2026); ABL Bio website: home and ABL001 pipeline pages (accessed October 2026); Handok Pharmaceuticals English website home page (accessed October 2026)
Data as ofOctober 14, 2026
Prepared byAI research agent (Claude); not yet reviewed by a person

Company statements of prevalence

United States

Incidence: Compass Therapeutics corporate presentation, July 2026

“>26,500” (opens the source at this quote in a new tab)

“patients diagnosed with BTC (growing to ~34K by 2037)” (opens the source at this quote in a new tab)

Cited source: 2.1 Rahib 2021; 2.2 Gunchick 2026

Compass Therapeutics (2026) corporate presentation, July 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number treated (first-line treatment): Compass Therapeutics corporate presentation, July 2026

“>24,000 patients Receive 1L treatment (10% resection and 5% cure)” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Compass Therapeutics (2026) corporate presentation, July 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number treated (second-line treatment): Compass Therapeutics corporate presentation, July 2026

“>17,000 patients Receive 2L treatment (70% of1L patients)” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Compass Therapeutics (2026) corporate presentation, July 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Eligible population: Compass Therapeutics corporate presentation, July 2026

“Over 15K patients/yr potentially eligible for tovecimig” (opens the source at this quote in a new tab)

“>15,000 patients Eligible for tovecimig (~85% have no actionable mutations)” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Compass Therapeutics (2026) corporate presentation, July 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Incidence: Compass Therapeutics Form 10-K for 2025, March 2026

“We estimate that there are approximately 26,500 patients newly diagnosed with BTC in the United States each year” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Compass Therapeutics (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Incidence: Compass Therapeutics press release, November 2025

“Recent claims-based market research shows ~25,000 patients are diagnosed with BTC annually in the United States alone, and tovecimig could provide hope for the vast majority of patients in the second line who have no approved therapeutic option.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Compass Therapeutics (2025) press release, November 5, 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Incidence: Compass Therapeutics corporate presentation, August 2025

“Annual BTC incidence in the U.S. (~23K+ in 2023)” (opens the source at this quote in a new tab)

Cited source: 2.3 Compass Therapeutics 2025

Compass Therapeutics (2025) corporate presentation, August 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Incidence: Compass Therapeutics press release, April 2025

“Biliary tract cancer is estimated to affect approximately 23,000 patients annually in the United States. For the approximately 85% of patients with BTC whose tumors do not harbor an actionable mutation with an approved targeted therapy, there is currently no FDA-approved treatment in the second line setting.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Compass Therapeutics (2025) press release, April 1, 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Incidence: Compass Therapeutics Form 10-K for 2024, February 2025

“We estimate that there are approximately 23,000 patients diagnosed with BTC in the United States each year” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Compass Therapeutics (2025) Form 10-K for 2024, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Incidence: Compass Therapeutics press release, April 2024

“In the United States approximately 23,000 cases of BTC are diagnosed annually,” (opens the source at this quote in a new tab)

“including cholangiocarcinoma, gallbladder, and ampullary subtypes.” (opens the source at this quote in a new tab)

Cited source: 2.4 Marcano-Bonilla 2016

Compass Therapeutics (2024) press release, April 25, 2024, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Incidence: Compass Therapeutics Form 10-K for 2023, March 2024

“There are an estimated 18,600 patients diagnosed with BTC in the U.S. each year” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Compass Therapeutics (2024) Form 10-K for 2023, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Europe

No evidence found.

Global

Incidence (worldwide): Compass Therapeutics Form 10-K for 2025, March 2026

“over 200,000 patients worldwide.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Compass Therapeutics (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Other countries and regions

No evidence found.

Geography not stated

No evidence found.

Sources the company cites

Rahib 2021

Reference as the company lists it

“1. PMID: 33825840” (opens the source at this quote in a new tab)

Compass Therapeutics (2026) corporate presentation, July 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the nearest figure

“Table 1. Estimated Incidences Based on 2016 National Population Projections and Average Annual Percentage Change (2011-2015) in Incidence Rates” (opens the source at this quote in a new tab)

“Liver and intrahepatic bile duct Male 31 000 46 000 65 000 Female 12 000 22 000 34 000 Total 43 000 68 000 100 000” (opens the source at this quote in a new tab)

Rahib 2021, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Gunchick 2026

Reference as the company lists it

“2. Gunchick et al., CCF Annual Conference 2026” (opens the source at this quote in a new tab)

Compass Therapeutics (2026) corporate presentation, July 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the figure

Not quoted: Conference presentation at the Cholangiocarcinoma Foundation Annual Conference 2026; no published abstract or document was located.

Compass therapeutics 2025

Reference as the company lists it

“1. CMPX - commissioned market research (2025);” (opens the source at this quote in a new tab)

Compass Therapeutics (2025) corporate presentation, August 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the figure

Not quoted: Unpublished market research commissioned by the company; no document or address.

Marcano-Bonilla 2016

Reference as the company lists it

“Marcano-Bonilla, L. et al, Chin Clin Oncol. 2016 Oct; 5(5):61, p.1-31.” (opens the source at this quote in a new tab)

Compass Therapeutics (2024) press release, April 25, 2024, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the figure

“In the United States (US) approximately 23,000 cases of BTC are diagnosed annually” (opens the source at this quote in a new tab)

Marcano-Bonilla 2016, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

References

  1. Compass Therapeutics (2024) Form 10-K for 2023 (opens in a new tab)
  2. Compass Therapeutics (2024) press release, April 25, 2024 (opens in a new tab)
  3. Compass Therapeutics (2025) corporate presentation, August 2025 (opens in a new tab)
  4. Compass Therapeutics (2025) Form 10-K for 2024 (opens in a new tab)
  5. Compass Therapeutics (2025) press release, April 1, 2025 (opens in a new tab)
  6. Compass Therapeutics (2025) press release, November 5, 2025 (opens in a new tab)
  7. Compass Therapeutics (2026) corporate presentation, July 2026 (opens in a new tab)
  8. Compass Therapeutics (2026) Form 10-K for 2025 (opens in a new tab)
  9. Marcano-Bonilla 2016 (opens in a new tab)
  10. Rahib 2021 (opens in a new tab)